Fast chemical communication in the nervous system is mediated by neurotransmitter-gated ion channels. The prototypical member of this class of cell surface receptors is the cation-selective nicotinic acetylcholine receptor. As with most ligand-gated ion channels, nicotinic receptors assemble as oligomers of subunits, usually as hetero-oligomers and often with variable stoichiometries 1 . This intrinsic heterogeneity in protein composition provides fine tunability in channel properties, which is essential to brain function, but frustrates structural and biophysical characterization. The α4β2 subtype of the nicotinic acetylcholine receptor is the most abundant isoform in the human brain and is the principal target in nicotine addiction. This pentameric ligand-gated ion channel assembles in two stoichiometries of α-and β-subunits (2α:3β and 3α:2β). Both assemblies are functional and have distinct biophysical properties, and an imbalance in the ratio of assemblies is linked to both nicotine addiction 2,3 and congenital epilepsy 4,5 . Here we leverage cryoelectron microscopy to obtain structures of both receptor assemblies from a single sample. Antibody fragments specific to β2 were used to 'break' symmetry during particle alignment and to obtain highresolution reconstructions of receptors of both stoichiometries in complex with nicotine. The results reveal principles of subunit assembly and the structural basis of the distinctive biophysical and pharmacological properties of the two different stoichiometries of this receptor.
, and at low resolution the subunit identities may not be readily distinguishable. Heterogeneity in subunit assembly adds to the challenges in particle alignment. In the nicotinic receptor, the α-and β-subunits have nearly identical secondary structural features, which makes them and their multiple assemblies indistinguishable at low resolution. We raised monoclonal antibodies against the recombinant α4β2 nicotinic receptor and isolated high-affinity antigen-binding (Fab) fragments to structurally distinguish α-subunits from β-subunits within the pseudo-symmetric pentamer. In contrast to our earlier crystallographic studies, in which we optimized expression conditions to produce more-or-less exclusively the 2α:3β assembly 8 , here we intentionally produced a mixed population of both stoichiometries of the α4β2 receptor (2α:3β and 3α:2β). We co-purified the receptor-Fab complex, and prepared sample grids for cryo-EM (Extended Data Fig. 1a and Methods). Fab has little or no effect on [ 3 H]-nicotine binding and activation of the channel (Extended Data Fig. 1b-d) .
Single particle cryo-EM data collection and processing revealed two distinct receptor populations, one with two Fabs bound and one with three Fabs bound, corresponding to the 3α:2β and 2α:3β stoichiometries, respectively (Extended Data Fig. 2 ). We obtained cryo-EM maps of the two stoichiometries to approximately 3.5 Å resolution for the receptor and approximately 4 Å resolution for the entire complex including Fab (Fig. 1a-d and Extended Data Figs. 2, 3), with map quality that was substantially improved over that of the crystallographic structure of the 2α:3β assembly 8 (Extended Data Table 1 and Extended Data Figs. 4-6). Each receptor assembly is cylinder-shaped, with a large extracellular vestibule and funnel-shaped transmembrane channel. Fabs interact exclusively with the extracellular domain (ECD) of the β2 subunits (Extended Data Fig. 1e-h ). The agonist nicotine was included throughout purification, and density for it was observed at α-β and α-α interfaces in the receptor ECD. Nicotine stabilizes the ion channel in a putative closed-desensitized conformation.
We sought to understand why we did not observe more than two subunit assemblies 3,9,10 , given that our structures demonstrate the occurrence of all possible interfaces between α4 and β2 subunits. Each stoichiometry contains two α-β and two β-α interfaces, plus a third unique interface type: one α-α (3α:2β) or one β-β (2α:3β) interface ( Fig. 2a-d ). Our reconstructions reveal that in an agonist bound, desensitized state, the α-α interface buries the most protein surface area from solvent, followed by the α-β and β-α interfaces (Fig. 2e) . The β-β interface has the smallest amount of buried surface area. Calculated interfacial free energies predict preferential assembly of α-β, followed by β-α as the most favourable, followed by α-α. β-β is the least favourable interface. A polar fenestration formed at the β-β interface is large enough (more than 5 Å) for hydrated ions to pass through ( Letter reSeArCH area buried at this interface class. These observations suggest that the more favourable α-β and β-α interfaces assemble first, followed by incorporation of the fifth subunit to create the unique interface as the final step in pentamer formation. Superposition of like subunits, both within an assembly and between assemblies, reveals no substantial conformational differences among α-subunits. However, there is a rigid body twist of 4.4° in the ECDs relative to the transmembrane domains (TMDs) of the two β-subunits that compose the unique β-β interface compared to all other β2 subunits (Extended Data Fig. 6d-h ). This conformational heterogeneity in β2 subunit structure is likely to add to the instability of the β-β interface. These structural observations suggest that the 3α:2β stoichiometry would be the predominant assembly in the absence of other factors, consistent with observations in rat motor cortex 11 and in expression of recombinant mammalian receptors 9 . In our sample preparation, we exploited nicotine and low temperature, two factors that are known to shift the stoichiometry towards the 2α:3β assembly, during viral transduction to boost overall receptor expression 9 . Analysis of interfaces and subunit conformation suggested an order of subunit incorporation in the observed 2α:3β and 3α:2β assemblies driven by free energy, but did not explain why other theoretically possible subunit stoichiometries were not observed. To address this question, we superimposed the unique interface from each assembly (α-α or β-β) upon itself to build up theoretical homopentameric assemblies, wherein all interfaces except for the final interface would be equivalent to the starting, experimentally observed interface. We then analysed this last, non-experimental interface and found in the 5α assembly a marked increase in surface area buried compared to the experimental α-α interface (3,849 Å 2 versus 2,923 Å 2 ) and 42 atomic clashes (Extended Data Fig. 8 ). Put simply, homopentameric α4 assemblies are unfavourable because they pack too tightly. Conversely, in the 5β assembly, at the final, non-experimental interface, we observed a gap between subunits resulting in a large decrease in surface area buried compared to the experimental β-β interface (1,051 Å  2 versus 2,086 Å   2 ). Thus, β-β interfaces pack such that they create too obtuse an angle to effectively close the pentameric ring. We added one α-β interface into each of these homopentameric assemblies to examine the final theoretically possible subunit stoichiometries and observed a small decrease in the number of clashes in the 4α:1β assembly (39 clashes), and a small increase in the surface area buried at the 1α:4β assembly (1,301 Å 2 ). We conclude from these comparisons that only two stoichiometries are observed because only one α-α or one β-β interface can be accommodated in the pentamer while maintaining favourable interactions at all interfaces around the pentameric ring.
The ratio of the two observed assemblies of the α4β2 receptor in vivo is tunable and context-specific and has been linked to genetic disorders and addiction [2] [3] [4] [5] . Smoking, as well as nicotine added to cultured cells, preferentially upregulates the 2α:3β stoichiometry 2 . Mutations that shift the stoichiometry towards either the 3α:2β or 2α:3β assembly result in autosomal-dominant nocturnal frontal lobe epilepsy 4, 5 . A high-penetrance form of this syndrome is linked to a serine-to-leucine mutation in the α4 subunit, at the 10′ position in the M2 pore-lining helix (Extended Data Fig. 6c ), which results in a shift in subunit stoichiometry towards the 3α:2β assembly 4 . The mechanism underlying this shift in assembly has been unclear. In the cryo-EM structures, we observe this serine side chain orienting into a hydrophobic pocket in the adjacent subunit, regardless of the identity of that subunit. Mutation from the polar serine to the hydrophobic leucine should be energetically favourable, given the local environment. This substitution would favour assembly of the 3α:2β stoichiometry because with three mutated α-subunits, three interfaces would have improved hydrophobic interactions and fewer unsatisfied hydrogen bonding interactions, contrasted with only two such favourable interfaces in the 2α:3β assembly.
The 3α:2β assembly is classically described as the low-sensitivity isoform of the α4β2 receptor, with half maximal effective concentration (EC 50 ) values for agonist approximately 100-fold higher than for the 2α:3β stoichiometry 9 . We sought to understand this agonist sensitivity difference in the context of receptor structure. The high-sensitivity neurotransmitter sites in the α4β2 receptor are found at the α4-β2 subunit interfaces in ECDs. The α-α interface in the 3α:2β assembly may serve as a low-sensitivity neurotransmitter site, occupation of which is necessary to obtain a full response 12, 13 . We included 1 mM nicotine in our preparation to saturate high-and low-sensitivity sites. A comparison of the four classes of interface reveals density for nicotine at the low-sensitivity α-α interface in the 3α:2β stoichiometry in addition to the high-sensitivity α-β interfaces in both stoichiometries of the α4β2 receptor (Fig. 3a, b and Extended Data Fig. 9 ). All α-β interfaces are qualitatively equivalent and are consistent with the crystal structure 8 in the binding orientation of nicotine and the interactions it makes at this interface class. The binding orientation of nicotine at the α-β neurotransmitter binding sites is distinct from that observed at the α-α binding site. In the α-β interfaces, nicotine is oriented with its long axis approximately parallel to the pore axis, with its pyridine ring oriented away from the membrane. At the α-α interface ( Fig. 3a and Extended Data Fig. 9 ), the pyridine ring of nicotine orients towards the pore axis with the molecule tilted off the membrane normal. This pose of nicotine in the α-α binding site is consistent with crystal structures of other α4β2 agonists bound to a soluble extracellular domain engineered to mimic the α-α binding site in α4β2
14 . This trend suggests that the distinct binding orientation is a meaningful feature of the low-sensitivity α-α binding site. The difference in sensitivity between the classical α-β neurotransmitter binding site (high sensitivity) and the unique α-α binding site Letter reSeArCH (low sensitivity) has been attributed to three amino acid positions on the complementary (−) face of the binding pocket: V111/F119/L121 for the β2 (−) subunit and H116/Q124/T126 for the α4 (−) subunit 14, 15 ( Fig. 3c, d and Extended Data Fig. 9 ). In the α-β site ( Fig. 3b and Extended Data Fig. 9 ), the three hydrophobic residues from the β2 (−) subunit provide a surface of van der Waals contacts that orients the pyridine ring of nicotine, locking it in the aromatic box in a vertical position. In the α-α interface, two of the three variant amino acid positions of α4 (−), T126 and Q124, by the nature of being shorter and polar amino acids, provide a less compact and more hydrophilic site that allows the alternative binding orientation.
Owing in part to limited high-resolution structural information for heteropentameric assemblies, the role of the pseudo-agonist sites, or interface sites in the ECD that do not bind agonist, has been relatively unexplored. Previous crystallographic work revealed the molecular architecture of the pseudo-agonist sites 8 , and here we extend this analysis to all interfaces found in the two stoichiometries of the α4β2 nicotinic acetylcholine receptor (Fig. 3c, d ). The uniqueness of these pseudo-agonist site interfaces stems from the amino acid sidechains presented by β2 when it occupies the principal ( + ) side of the subunit interface. Of particular interest is R149, which would electrostatically and sterically impede agonists from binding and is positioned to form cation-π interactions with the sandwiching aromatic residues Y95 and Y196 from β2 ( + ) (Fig. 3c, d ). This intramolecular interaction is conserved among all pseudo-agonist binding interfaces between the two assemblies; furthermore, in the closed, presumably desensitized conformations presented here, all the β-α pseudo-agonist sites in both assemblies appear to be structurally equivalent. We speculate that the guanidium group of R149, which chemically and structurally mimics the nicotinic pharmacophore, may act in part as a covalent agonist, potentiating activation.
The two α4β2 receptor assemblies have different permeation properties: the 3α:2β assembly is about threefold more permeable to Ca 2+ than the 2α:3β assembly 16 and has a higher single channel conductance 9 . Both permeation pathways are strongly electronegative, as would be expected for a cation-selective channel, with the 3α:2β assembly having a stronger electronegative potential throughout (Fig. 4a, b ). These differences in electrostatic potential are localized to the extracellular vestibule and the junction of the ECD and TMD. The stronger electronegative potential seen in the extracellular vestibule of the 3α:2β assembly could not be predicted from sequence alone, as the acidic side chains lining the extracellular vestibule that are thought to affect conductance are conserved between the α4 and β2 subunits 17 . The continuity of the electronegative potential is interrupted in the 2α:3β assembly at the junction between the ECD and TMD, and results from opposing charges at the 20′ position, E268 in 3α:2β and K260 in 2α:3β, in the pore-lining M2 α-helices (Fig. 4c) . Point mutations at the 20′ position have demonstrated that having a negative charge at this extracellular entrance to the channel pore is an important determinant of conductance in nicotinic receptors 18 and calcium permeability in cationselective Cys-loop receptors 16, 19 . In the α4β2 receptor specifically, mutational studies with concatemers 16 have shown that increasing the proportion of negative charges at this position correlates directly with increasing permeability to Ca
2+
. Thus, the difference in charge at the 20′ position is a principal determinant of the different permeation properties of the two receptor subunit assemblies. A caveat to these comparisons is that our electron microscopy construct lacks much of the receptor's intracellular domain, a region that has a role in subunit assembly and ion conductance in the structurally homologous 5-HT 3 receptor 19, 20 . Analysis of the transmembrane pore reveals that both α4β2 receptor assemblies taper to a constriction point created by glutamates present in all subunits, located at the −1′ position of the M2 α-helices, where the pore interfaces with the cytosol (Fig. 4c ). The 3α:2β assembly has a smaller constriction point, a diameter of 2.4 Å compared to 3.2 Å ( Fig. 4d and Extended Data Fig. 10 ), which is consistent with the more tightly packed α-α interface compared to the β-β interface in the 2α:3β assembly ( Fig. 2e and Extended Data Figs. 7, 8). Early studies on permeation through different channel classes suggested that permeation through nicotinic receptors (unlike for K + channels) occurs with the ion at least partially hydrated 21 . The smallest physiologically permeant ion is Na + , with a crystal diameter of about 1.9 Å. Addition of a single equatorial water molecule (diameter 2.8 Å) raises the diameter of the permeant species above the size of both constriction points. With the caveat that the structure was determined in the presence of detergent and is not in a native lipid membrane, the constriction diameter is consistent with the pore representing a non-conducting, agonist-bound desensitized state.
Reconstitution of nicotinic receptors into defined lipid preparations has demonstrated that cholesterol is important for nicotinic receptor function 22 . We tested cholesterol derivatives in thermal stabilization assays 23 and found that the water-soluble cholesterol analogue 
ig. 3 | Agonist and pseudo-agonist binding sites. a-d, Molecular details of the α-α (a) and α-β (b) nicotine-binding interfaces and corresponding regions at the β-β (c) and β-α (d) interfaces. Top row is synaptic perspective viewed parallel to channel axis. Nicotine and interacting residues are shown as sticks. Nicotine density is displayed as blue mesh. In the bottom row, loop C backbone is hidden.
Letter reSeArCH cholesteryl-hemisuccinate (CHS) potently stabilizes the receptor; thus, we included it throughout purification of the receptor. We identified two putative cholesterol molecules per subunit in the electron microscopy density maps (Extended Data Fig. 11 ). These sausage-shaped densities are found in pairs located at the receptor periphery along the intracellular half of the transmembrane domain, where they flank the subunit interfaces. When viewed at the interface, each putative cholesterol molecule interacts almost exclusively with one subunit and one adjacent cholesterol molecule. Each pair of cholesterol molecules shares a single amino acid contact that bridges these intrasubunit sites (Extended Data Fig. 11c, d ). These intrasubunit sites contrast with intersubunit binding sites found for cholesterol and potentiating neurosteroids in GABA A receptor chimaeras 24, 25 , and are distinct from the intrasubunit site identified for inhibitory neurosteroids in a GABA A receptor chimaera 25 (Extended Data Fig. 11f) . Comparison of the cholesterol positions in the α4β2 structures suggests that the orientations of the two molecules at an interface are dictated by the identity of the subunit on the principal side. When the principal subunit is β2, the cholesterols are oriented parallel to the pore axis; however, when the principal subunit is α4, the apical ends of both molecules tilt towards the principal face. The cholesterol binding site on the principal subunit is a bowl-shaped surface formed by the junction of the M3, MX and M4 helices. Close examination of this binding site reveals only a single amino acid position that is non-isosteric between the two subunit types, located on the penultimate helical turn in the M3 transmembrane helix. In β2 subunits this residue is a cysteine (C292) and in α4 subunits it is a phenylalanine (F300; Extended Data Fig. 11c-e) . The bulky phenylalanine residue is likely to prevent access to the apical portion of the binding region observed when β2 subunits form the principal face. Analysis of human Cys-loop receptor sequences reveals that a small hydrophobic residue that would allow this axial binding mode is conserved in neuronal β2 and β4 subunits as well as the muscle-type β1 subunit. Meanwhile, in all α-subunits from cation-selective receptor types, a bulky hydrophobic residue (F, I, L or M) is conserved at this position. Our assignment of this cholesterol binding site is consistent with mapping studies using photo-activatable cholesterol analogues 26, 27 . Here we used single particle cryo-EM coupled with antibody fragments to determine structures of both stoichiometries of the α4β2 nicotinic receptor from one experimental preparation. Comparison of the structures reveals principles underlying subunit assembly and the differences in permeation properties between the two stoichiometries. We observed agonist binding at the non-canonical α-α subunit interface, differentially stabilized by residues unique to this interface class. The structure further allowed mapping of putative cholesterol sites on the surface of the transmembrane domain near the cytosolic junction. This study provides a framework for further biophysical analysis of the allosteric interfacial sites, therapeutic targeting of these sites with modulators akin to benzodiazepines, and more broadly, a general approach for resolving the structural biology of heterogeneous assemblies.
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Any Methods, including any statements of data availability and Nature Research reporting summaries, along with any additional references and Source Data files, are available in the online version of the paper at https://doi.org/10.1038/s41586-018-0081-7. assembly showing the permeation pathway coloured by electrostatic potential. b, As in a, but for the 2α:3β assembly. c, M2 α-helices from opposing α4 (green) and β2 (blue) subunits from the 3α:2β assembly with sidechains shown for pore-lining residues. Purple spheres indicate pore diameters over 5.6 Å; green are 2.8-5.6 Å; red are less than 2.8 Å. d, Pore diameter for the α4β2 receptor 2α:3β and 3α:2β assemblies from the cryo-EM study compared to the crystal structure of the 2α:3β assembly (Protein Data Bank (PDB) accession 5KXI 8 ). The zero value along the y-axis of the plot is aligned with the α-carbon of the −1′ position. Uncertainty in the position of most acidic sidechains in EM density maps adds ambiguity to the constriction point diameters defined by the −1′ glutamates. 
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MEthodS
Nicotinic receptor expression and purification. The human α4 and β2 nicotinic receptor genes were provided by J. Lindstrom at the University of Pennsylvania. Deletion constructs used for expression and structural analysis lack a large portion of the intracellular domain of the receptor, as previously described 8 . These genes encode the native signal peptides, residues 1-338 and 556-601 in the α4 subunit and residues 1-330 and 417-477 in the β2 subunit (residue numbering here is for the wild-type mature, signal-peptide-cleaved protein sequence). To promote good biochemical behaviour a Glu-Arg linker was inserted in the MX-M4 junction, between Phe559 and Ser560 in the α4 subunit and between Gln420 and Ser421 in the β2 subunit. For purification purposes a Strep-tag was inserted at the C terminus of the β2 subunit preceded by a Ser-Ala linker. The genes were subcloned into the pEZT bacmam expression vector 28 and viral titration and protein expression in GnTI-HEK cells (ATCC CRL-3022, not mycoplasma tested) were performed as previously described 28 with modifications. We transduced 3.2 l of suspension GnTI-cells with multiplicities of infection (MOIs) of 0.5:0.5 for the α4 and β2 subunits, respectively, to promote expression of two receptor assemblies. Nicotine (Sigma-Aldrich) and sodium butyrate (Sigma-Aldrich) were added at the time of transduction to 0.1 mM and 3 mM, respectively. At the time of transduction, suspension cells were moved to 30 °C and 8% CO 2 . Cells were collected after ~72 h by centrifugation, resuspended in 20 mM Tris, pH 7.4, 150 mM NaCl (TBS buffer), 1 mM nicotine and 1 mM phenylmethanesulfonyl fluoride (Sigma-Aldrich), and disrupted using an Avestin Emulsiflex. Lysed cells were centrifuged for 15 min at 10,000g; supernatants containing membranes were centrifuged for 2 h at 186,000g. Membrane pellets were mechanically homogenized and solubilized for 1 h at 4 °C in a solution containing TBS, 40 mM n-dodecyl-β-d-maltopyranoside (DDM; Anatrace), 1 mM nicotine and 0.2 mM CHS (Tris salt, Anatrace). Solubilized membranes were centrifuged for 40 min at 186,000g then passed over high capacity Strep-Tactin (IBA) affinity resin. The resin was washed with Size Exclusion Chromatography (SEC) buffer containing TBS, 1 mM DDM, 1 mM nico tine, 0.2 mM CHS and 1 mM TCEP (Thermo Fisher Scientific) and eluted in the same buffer containing 5 mM desthiobiotin (Sigma-Aldrich). Generation of monoclonal antibodies and Fab fragments. The 12H2 monoclonal antibody (mAb) against the α4β2 nicotinic receptor (IgG1, κ) was raised by D. Cawley (Monoclonal Core, Vaccine and Gene Therapy Institute, OHSU) using standard methods. Hybridomas were generated by immunization of mice (female BALB/c) with α4β2 receptor protein purified in DDM, followed by fusion of splenocytes with mouse myeloma cells and selection of clones by enzyme-linked immunosorbent assay. The mAb was purified from hybridoma cell supernatant by cation exchange and protein A affinity chromatography. High affinity and specificity of the antibody for properly folded pentameric α4β2 receptor was assessed using Fluorescence-SEC (FSEC) with GFP-tagged receptor (shift in elution volume) and by western blot (no binding). The top candidate antibodies were then more thoroughly assessed using FSEC monitoring tryptophan fluorescence with purified α4β2 receptor and Fab fragments to ensure fidelity of the α4β2-Fab complex and to estimate receptor:Fab stoichiometry. α4β2-Fab complexes were co-purified, then re-injected in analytical FSEC to test for dissociation under these dilute conditions over a Sepax SRT SEC-500 (4.6 × 300 mm) gel filtration column. Fabs that did not dissociate were qualitatively deemed to have sufficiently high affinity to use in EM studies. The 12H2 Fab fragment used here was generated by papain cleavage of whole antibody at a final concentration of 1 mg/ml for 2 h at 37 °C in 50 mM NaPO 4 , pH 7.0, 1 mM EDTA, 10 mM cysteine and 1:100 (w:w) papain. Digestion was quenched using 30 mM iodoacetamide at 25 °C for 10 min. Fab was purified by cation exchange using a Hi-Trap SP column in 10 mM sodium citrate pH 5.0 and a NaCl gradient elution. Cloning and sequencing of Fab heavy and light chain genes were performed from mouse hybridoma cells. Cryo-EM sample preparation. Purified α4β2 from affinity chromatography was mixed with Fab in a 1:2 (w:w) ratio and injected over a Superose 6 Increase 10/300 GL column (GE) equilibrated in SEC buffer. Peak fractions were assayed by SEC, monitoring tryptophan fluorescence. The peak fraction was concentrated fourfold to an A280 of 5.9 in SEC buffer, ultracentrifuged, and used directly to prepare EM grids. Three microlitres of purified α4β2-nicotine-Fab complex was applied to glow-discharged gold R1.2/1.3 300 mesh holey carbon grids (Quantifoil) and immediately blotted for 4 s at ~100% humidity and 4 °C, then plunge-frozen into liquid ethane cooled by liquid nitrogen using a Vitrobot Mark IV (FEI). Cryo-EM image collection and processing. Two separate data sessions were taken on a Titan Krios electron microscope (FEI) operated at 300 kV. Images were recorded on a K2 Summit direct electron detector (Gatan) equipped with GIF quantum energy filter (20 e − V) (Gatan) in super-resolution mode (super-resolution pixel size: 0.535 Å per pixel). In the first session, 3,323 images were collected and each micrograph in the first session was exposed for 15 s with a dose rate of ~5 e − /A 2 /s (total specimen dose, ~75 e − /A 2 ), and 30 frames were captured per micrograph. In the second session, 2,588 images were collected and each micrograph in the second session was exposed for 10 s with ~5 e − /A 2 /s dose rate (total specimen dose, ~50 e − /A 2 ), and 40 frames were captured per micrograph. Images were recorded using the automated-acquisition program EPU (FEI) with defocus values varied from 0.5 µm to 4.5 µm.
Dose-fractionated images (movies) were gain normalized, 2 × Fourier binned (resulting in a pixel size of 1.07 Å per pixel), aligned, dose-weighted and summed using Unblur 29 . Defocus values were estimated using GCTF 30 . A total of 5,166 micrographs were manually selected and used for further analysis (2,836 out of 3,323 from the first session and 2,330 of 2,588 from the second session). Approximately 100 particles were manually picked and subjected to reference-free 2D class averaging in RELION 2.1 31, 32 . Resulting references were then used for auto-picking in RELION 2.1 for a subset of 10 images, then the classification process was repeated to obtain good references for auto-picking on all images. Following auto-picking, micrographs were manually inspected, and false-positive particles were manually removed. Curation of auto-picked particles resulted in a total of 649,773 particles. 516,450 particles were selected following 2D classification in RELION. Two-hundred particles from 30 different 2D classes (6,000 particles in total) were used to generate an ab initio model in RELION. 3D classification using eight classes resulted in six good classes (403,246 particles) that could be divided into to two distinct categories based on Fab occupancy and subunit-defining features, representing the 3α:2β (139,551), and 2α:3β (263,695) stoichiometries of the α4β2 receptor. 3D refinement of these two pooled particle sets yielded reconstructions of the overall receptor-Fab complexes at ~4.0 Å resolution. The Fab molecules, in particular the peripheral constant domains, were poorly resolved, and of less biological interest to us, so we focused our effort on the receptor. Removing the Fab regions from the global resolution calculations results in reconstructions for the 3α:2β assembly at 3.7 Å and for the 2α:3β assembly at 3.4 Å resolution, consistent with side chain features throughout the density maps. All global resolutions were estimated by applying a soft mask around the protein density and the gold-standard Fourier shell correction (FSC) = 0.143 criterion. ResMap 33 was used to estimate the local resolution.
Model building, refinement and validation. The higher resolution 2α:3β assembly was built first. The X-ray coordinates (PDB accession code 5KXI) were docked into the density map. Secondary structural features that are distinct between the two stoichiometries (loop C and α1 helix, Fig. 1 ) were used to guide the initial rigid body fit using UCSF Chimera 34 . SwissModel 35 was used to generate a homology model of the Fab light chain using PDB entry 4TPR and for the heavy chain using PDB entry 2ZJS. These chains were docked into the EMD density at one Fab site. Manual adjustments of the receptor-Fab structure were then performed in Coot 36 . The ECD and transmembrane domain (TMD) halves of each subunit, and the variable and constant halves of each Fab, were rigid body fitted into the density map. The epitope binding loops of the Fabs were rebuilt into unambiguous density at the site of interaction with the receptor, and then this first Fab molecule was copied into the two additional sites in the 2α:3β assembly. The map quality for the receptor exceeded that from the earlier X-ray structure, which allowed for more residues to be built at the N termini and in the linkers connecting the MX amphipathic helix with the M4 helix. There was unclear density and thus a gap in the connectivity in the MX-M4 linker for 7 residues in α4 subunits and 10 residues in β2 subunits. There was improved density for side chains and better connectivity in the ECD loops, in particular loop C in the β-subunits. After rebuilding in Coot, global real space coordinate and B factor refinement were performed in Phenix 37 . The cryo-EM density maps drew our attention to a notable conformational difference in the loop C of β2 subunits compared to that modelled in the crystallographic structure 8 . We observed continuous density for this substructure in all β2 subunits in EM maps that resolve loop C in a conformation bending out and away from the subunit interface (Fig. 3 c, d and Extended Data Fig. 6a-c) . This conformation was independent of whether Fab was bound to the adjacent (−) subunit or not (Extended Data Fig. 1e, f) . In the crystal structure, loop C in β2 subunits was modelled in a conformation packed against the (−) subunit, roughly akin to the conformation of loop C in α4 subunits. The crystallographic modelling was based on clear electron density for loop C in one β2 subunit that was at a crystal contact (Extended Data Fig. 6a-c) . We thus suggest that an open conformation of loop C in β2 subunits is the proper one.
The validation to test for overfitting of the model was performed as previously described 38 . In brief, the atom positions of the final refined model were randomly displaced by a maximum of 0.5 Å using PDBSET in the CCP4 suite 39 . This perturbed model was then refined in Phenix in real space against the first half map of the reconstruction comprising 50% of the particles. A map versus model FSC comparison was made for this model versus the map used in its refinement ('work'), as well as the same model versus the half map not used in refinement ('free'). The FSC curves of map versus model agree well (Extended Data Figs. 4, 5) .
Sequences used in alignments were retrieved from the UniProtKB database 40 . Sequence alignments were made using PROMALS3D 41 . Subunit interfaces includ-
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Extended Data Fig. 1 | Biochemistry, binding, electrophysiology and  α4β2-Fab interactions. a, Size-exclusion 14 and 1.09, respectively) . Plotted results are from a representative experiment performed in triplicate. c, Representative two-electrode voltage clamp (−60 mV) recordings of oocytes injected with cRNAs for the α4 and β2 subunits in ratios to bias assembly,1α:5β (top two traces) and 5α:1β (bottom two traces) for the 2α:3β and 3α:2β assemblies, respectively. The experiments were performed in the presence and absence of Fab to assess the effect of Fab on receptor gating. Each oocyte was perfused with 1 µM nicotine solution for about 2 min, washed with bath solution for 10 min and then perfused for about 2 min with 1 µM nicotine ± Fab. For samples where Fab was included, 1 µM final [Fab] was added directly to the oocyte bath following the first perfusion and allowed to incubate for 1.5 min before perfusing with a second solution containing 1 µM nicotine + 0.1 µM Fab. d, Bar graph quantifying peak currents before and after adding Fab. Currents were normalized to the amplitude of the first nicotine application. Appreciable current rundown was observed (assessed by applying nicotine without Fab as the second application). Change in peak current is similar in the presence and absence of Fab for both stoichiometries, suggesting no substantial effect on gating. n, number of oocytes; error bars, s.d. from mean. e-h, Fab-β-subunit interactions at the α-β, β-β, α-β, and α-α interfaces, respectively. With one exception, the Fab molecules interact exclusively with a single β-subunit. The exception is at the β-β interface, where the Fab on the complementary β-subunit forms one potential interaction with the preceding β-subunit. This interaction is displayed as a dashed line (f, inset). The conformation of the principal loop C at the β-β interface is indistinguishable from those where Fab is not interacting, suggesting that Fab does not affect the loop C conformation. Subunits are coloured as in Fig. 1 Letter reSeArCH Extended Data Fig. 8 | Basis of α4β2 heteromeric assembly. a, Cartoon representation of top view of observed (2α:3β and 3α:2β) and computational (4α:1β, 1α:4β, 5α and 5β) α4β2 pentameric assemblies. Assemblies on the top row (3α:2β, 4α:1β, and 5α) are arranged by increasing α4 composition. Assemblies on the bottom row (2α:3β, 1α:4β and 5β) are arranged by increasing β2 composition. Agonist binding sites are denoted by red circles. Buried interface areas (Å 2 ) for the interfaces analysed in b, c are listed below each pentameric assembly. Subunits are coloured in a as described below for b, c. b, Superposition of α-α from 3α:2β and final α-α interface in 5α homopentamer. Principal subunits (grey) were superimposed to highlight differences at the interface. Complementary (−) subunits are coloured light green for α-α from 3α:2β and dark green for the α-α interface in the 5α homopentamer. Sticks are displayed for amino acid clashes that have greater than 1.5 Å overlap assessed by Molprobity. c, Superposition of the β-β interface from 2α:3β and final β-β interface in the 5β homopentamer. Principal subunits (grey) were superimposed to highlight differences at the interface. Complementary (−) subunits are coloured light blue for the β-β interface from the 2α:3β assembly and dark blue for the final β-β interface in the 5β homopentamer. 
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